A study by investigators at Weill Cornell Medicine and NewYork-Presbyterian aims to answer one of COVID-19’s biggest mysteries: why do some people become severely ill, while others have no symptoms?
Higher levels of a type of fungus in the gut are associated with better outcomes for patients with a type of inflammatory bowel disease called ulcerative colitis who are treated with gut microbes from healthy donors.
A class of immune cells push themselves into an inflammatory state by producing large quantities of a serotonin-making enzyme, according to a study in mice led by scientists at Weill Cornell Medicine.
New cellular and molecular processes underlying communication between gut microbes and brain cells have been described for the first time by scientists at Weill Cornell Medicine and Cornell’s Ithaca campus.
A molecule best known for its association with migraines may be a key to new treatments for common worm infections as well as allergic inflammatory disorders such as asthma, according to a study from scientists at Weill Cornell Medicine and the National Institutes of Health.
A molecule that helps prevent fat accumulation in mammals is produced within fat tissues by stem-like cells that may be therapeutic targets for obesity and related disorders.
Researchers have long known that dysfunction in the body’s innate immune system breaks the first line of defense against invading pathogens, enabling diseases to flourish unchecked.
With a $7.5 million gift from the Friedman Family Foundation endowed by Stephen and Vice Chair Overseer Barbara Friedman, Weill Cornell Medicine has established an innovative cross-campus center dedicated to improving human health through research in the complex relationship between nutrition, inflammation and the development of disease.
Cells in the nervous system can “put the brakes” on the immune response to infections in the gut and lungs to prevent excessive inflammation, according to research by Weill Cornell Medicine scientists.
